8-K: Immunocore Reports Strong Q2 Revenue, Pipeline Progress

Immunocore Holdings plc announced robust second quarter 2025 financial results with significant revenue growth for KIMMTRAK and advancement across its oncology, infectious disease, and autoimmune pipelines.

Summary

• KIMMTRAK net product sales reached $98.0 million in Q2 2025, marking a 30% year-over-year increase.
• Total revenue for Q2 2025 was $97.964 million, up from $75.400 million in Q2 2024.
• The company reported a net loss of $10.3 million for Q2 2025, an improvement from a net loss of $11.6 million in Q2 2024.
• Cash, cash equivalents, and marketable securities stood at $882.8 million as of June 30, 2025, compared to $820.4 million at December 31, 2024.
• The Phase 3 TEBE-AM trial for 2L+ advanced cutaneous melanoma is on track to complete enrollment in the first half of 2026.
• Dose selection for the PRISM-MEL-301 Phase 3 trial in first-line advanced cutaneous melanoma is expected in the second half of 2025.
• Phase 1 single ascending dose HBV data for IMC-I109V will be presented at the 2025 AASLD Liver Meeting in November 2025.
• Clinical trial applications (CTA) or investigational new drug applications (IND) for autoimmune candidates IMC-S118AI (Type 1 Diabetes) and IMC-U120AI (Atopic Dermatitis) are on track for 2H 2025 and 2026, respectively.

Sentiment

Score: 8

Explanation: The company demonstrated strong commercial growth for its lead product, reduced its net loss, and maintained a healthy cash position. Significant progress was reported across its diverse clinical pipeline, including multiple Phase 3 trials and expansion into new therapeutic areas, indicating robust operational execution and future potential.

Positives

• KIMMTRAK net product sales grew by 30% year-over-year in Q2 2025, reaching $98.0 million, demonstrating strong commercial performance.
• The company's net loss decreased to $10.3 million in Q2 2025 from $11.6 million in Q2 2024, indicating improved financial efficiency.
• Cash, cash equivalents, and marketable securities increased to $882.8 million by June 30, 2025, providing a strong liquidity position.
• Significant progress in clinical trials, with the Phase 3 TEBE-AM trial on track for enrollment completion in 1H 2026 and PRISM-MEL-301 dose selection expected in 2H 2025.
• Global expansion of KIMMTRAK continues, with new country launches and completed price negotiations in key European markets like France and Germany, driving 71% YoY quarterly growth in Europe and international regions.
• The company is advancing its pipeline into new therapeutic areas, including infectious diseases and autoimmune diseases, showcasing platform diversity.

Negatives

• Research and development (R&D) expenses increased to $69.0 million in Q2 2025 from $51.1 million in Q2 2024, reflecting higher investment but also increased cash burn.
• Selling, general & administrative (SG&A) expenses rose to $42.8 million in Q2 2025 from $38.6 million in Q2 2024, driven by business support and global commercial expansion costs.
• The company expects to pay approximately $65 million in sales-related rebate accruals in the second half of 2025, which will impact cash flow.

Risks

• Worsening macroeconomic conditions, including changes in inflation and interest rates, and global geopolitical tension, could impact business, financial position, strategy, and anticipated milestones.
• Ability to obtain a clinical supply of current or future product candidates or commercial supply of KIMMTRAK or any future approved products.
• Ability to obtain and maintain regulatory approval of product candidates, including KIMMTRAK.
• Ability to establish and expand a commercial infrastructure and to successfully launch, market, and sell KIMMTRAK and any future approved products.
• Ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval in additional geographies in the future.
• Delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise.
• Ability to successfully demonstrate the safety and efficacy of product candidates and gain approval on a timely basis, if at all.
• Competition with respect to market opportunities.
• Unexpected safety or efficacy data observed during preclinical studies or clinical trials.
• Actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials or future regulatory approval.
• Need for and ability to obtain additional funding, on favorable terms or at all.
• Ability to obtain, maintain, and enforce intellectual property protection for KIMMTRAK or any of its product candidates.
• Success of current and future collaborations, partnerships, or licensing arrangements.

Future Outlook

Immunocore anticipates continued global expansion for KIMMTRAK in metastatic uveal melanoma, with potential future expansions into second-line advanced cutaneous melanoma and adjuvant uveal melanoma. The company expects to complete enrollment for the Phase 3 TEBE-AM trial in the first half of 2026 and select the go-forward dose for the PRISM-MEL-301 Phase 3 trial in the second half of 2025. Clinical trial applications for autoimmune candidates IMC-S118AI and IMC-U120AI are planned for the second half of 2025 and 2026, respectively. Data from the Phase 1 single ascending dose HBV trial for IMC-I109V will be presented in November 2025.

Management Comments

• "We are delighted to announce robust revenue for the first half of 2025, a 32% year-over-year increase. This is testament to our steadfast dedication to expanding access to KIMMTRAK in the US and across the globe."
• "Our Phase 3 TEBE-AM trial remains on schedule to complete enrollment in the first half of 2026, and we are making good progress with our other two Phase 3 trials: PRISM-MEL-301 and ATOM."
• "We are also advancing our Phase 1/2 trials in oncology and infectious diseases and preparing for the clinical trial applications for our autoimmune candidates, further underscoring the depth and diversity of our platform."

Industry Context

Immunocore operates in the highly competitive biotechnology sector, specializing in novel T cell receptor (TCR) bispecific immunotherapies. The strong revenue growth for KIMMTRAK, a first-in-class therapy for metastatic uveal melanoma, positions the company as a leader in this rare cancer space. Its pipeline expansion into broader oncology indications like cutaneous melanoma, infectious diseases (HIV, HBV), and autoimmune diseases (Type 1 Diabetes, Atopic Dermatitis) reflects a strategic move to diversify its platform beyond its initial success, addressing significant unmet medical needs across multiple large markets. The focus on functional cures for infectious diseases and tissue-specific immune modulation for autoimmune conditions represents innovative approaches within these fields.

Comparison to Industry Standards

• KIMMTRAK continues to be the standard of care in most markets where it is launched for metastatic uveal melanoma, indicating strong market adoption and competitive positioning against existing or older therapies.
• The company estimates a potential to address up to 4,000 previously treated advanced cutaneous melanoma patients with TEBE-AM, highlighting a significant unmet need where no therapy has shown an Overall Survival improvement post checkpoint inhibitors in a randomized clinical trial, differentiating its approach from current standards like anti-PD1 or BRAF therapy.
• For first-line advanced cutaneous melanoma, the PRAME portfolio aims to address an estimated 10,000 HLA-A*02:01 positive patients in the US and Europe, targeting a segment where improved progression-free survival and overall survival are still needed despite approved therapies.
• The estimated annual number of eligible patients worldwide who test positive for HLA-A*02:01 across all solid tumors is up to 150,000 for brenetafusp, suggesting a broad market opportunity compared to more narrowly targeted therapies.
• The company's ImmTAV and ImmTAAI platforms aim for 'functional cures' in infectious diseases and 'tissue-specific down modulation' in autoimmune diseases, respectively, which represent potentially transformative approaches compared to symptomatic management or broad immunosuppression common in these fields.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, reduced net loss, healthy cash position, and pipeline advancement, suggesting potential for future value creation.
• Patients: Continued global expansion of KIMMTRAK and progress in clinical trials for various diseases (melanoma, HIV, HBV, type 1 diabetes, atopic dermatitis) indicate potential for increased access to transformative medicines and new treatment options.
• Employees: Continued growth and pipeline expansion suggest stability and potential for further opportunities within the company.
• Customers (healthcare providers): Increased availability and continued efficacy of KIMMTRAK reinforce its position as a standard of care, supporting treatment decisions.

Next Steps

• Complete enrollment for the Phase 3 TEBE-AM trial in 1H 2026.
• Conduct dose selection for the PRISM-MEL-301 Phase 3 trial in 2H 2025.
• Present Phase 1 single ascending dose HBV data for IMC-I109V at the 2025 AASLD Liver Meeting in November 2025.
• File CTA/IND for IMC-S118AI (PPI x PD1) in type 1 diabetes in 2H 2025.
• File CTA/IND for IMC-U120AI (CD1a x PD1) in atopic dermatitis in 2026.
• Pay approximately $65 million in sales-related rebate accruals in 2H 2025.

Key Dates

Recommendation

The filing indicates strong operational and financial performance, with significant year-over-year revenue growth for its lead commercial product, KIMMTRAK, and a reduction in net loss. The company maintains a robust cash position, providing financial stability for ongoing operations and pipeline development. Crucially, Immunocore is making substantial progress across its diverse clinical pipeline, with multiple Phase 3 trials advancing on schedule and new candidates entering clinical development for high-unmet-need areas like infectious and autoimmune diseases. This combination of commercial success, financial health, and pipeline momentum suggests strong future growth potential, making it an attractive investment for long-term growth-oriented investors.

Keywords

Immunocore, KIMMTRAK, tebentafusp, uveal melanoma, cutaneous melanoma, PRAME, ImmTAC, biotechnology, oncology, infectious diseases, autoimmune diseases, clinical trials, drug development, biologics, TCR bispecifics, financial results